Cationic Polymeric Gene Delivery of β-Glucuronidase for Doxorubicin Prodrug Therapy

Journal of Gene Medicine

Volumn 1, Issue 6, 1999, Pages 407-414

  Fonseca, María José ^a   Storm, Gert ^a   Hennink, Wim E ^a   Gerritsen, Winald R ^b   Haisma, Hidde J ^b,c  

^a UTRECHT UNIVERSITY   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

Doxorubicin; GDEPT; Non viral; Poly(2 (dimethylamino)ethyl methacrylate; Polymer; Prodrug; Transfection

Indexed keywords

BACTERIA (MICROORGANISMS);

ANTINEOPLASTIC ANTIBIOTIC; ANTINEOPLASTIC ANTIMETABOLITE; BETA GLUCURONIDASE; CATION EXCHANGE RESIN; CYTOSINE DEAMINASE; DEAMINASE; DOXORUBICIN; DRUG CARRIER; DRUG DERIVATIVE; FLUCYTOSINE; GLUCURONIC ACID; LIPID; LIPOFECTAMINE; METHACRYLIC ACID DERIVATIVE; N (4 DOXORUBICIN N CARBONYL(OXYMETHYL)PHENYL) O GLUCURONYL CARBAMATE; N-(4-DOXORUBICIN-N-CARBONYL(OXYMETHYL)PHENYL)-O-GLUCURONYL CARBAMATE; NYLON; POLY(2 (DIMETHYLAMINO)ETHYL METHACRYLATE); POLY(2-(DIMETHYLAMINO)ETHYL METHACRYLATE); PRODRUG; RECOMBINANT DNA;

ARTICLE; BIOTRANSFORMATION; CARCINOMA; CELL CULTURE; CELL DEATH; CELL DIVISION; CHEMISTRY; CULTURE MEDIUM; DRUG EFFECT; DRUG SCREENING; ELECTRICITY; ENZYMOLOGY; FEMALE; GENE VECTOR; GENETIC TRANSFECTION; GENETICS; HUMAN; METABOLISM; OVARY TUMOR; PARTICLE SIZE; PATHOLOGY; PLASMID; REPORTER GENE;

ANTIBIOTICS, ANTINEOPLASTIC; ANTIMETABOLITES, ANTINEOPLASTIC; BIOTRANSFORMATION; CARCINOMA; CATION EXCHANGE RESINS; CELL DEATH; CELL DIVISION; CULTURE MEDIA, SERUM-FREE; CYTOSINE DEAMINASE; DNA, RECOMBINANT; DOXORUBICIN; DRUG CARRIERS; DRUG SCREENING ASSAYS, ANTITUMOR; ELECTROSTATICS; FEMALE; FLUCYTOSINE; GENES, REPORTER; GENETIC VECTORS; GLUCURONIC ACIDS; GLUCURONIDASE; HUMANS; LIPIDS; METHACRYLATES; NUCLEOSIDE DEAMINASES; NYLONS; OVARIAN NEOPLASMS; PARTICLE SIZE; PLASMIDS; PRODRUGS; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0033223554     PISSN: 1099498X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1521-2254(199911/12)1:6<407::AID-JGM71>3.0.CO;2-Q     Document Type: Article

References (25)

1. Niculescu-Duvaz I, Spooner R, Marais R, Springer C. Gene-directed enzyme prodrug therapy. Bioconjug Chem 1998; 9: 4-22.
2. Wang SM, et al. Specific activation of glucuronide prodrugs by antibody-targeted enzyme conjugates for cancer therapy. Cancer Res 1992; 52: 4484-4491.
3. Roffler SR, et al. Antineoplastic glucuronide prodrug treatment of human tumor cells targeted with a monoclonal antibody-enzyme conjugate. Biochem Pharmacol 1992; 42: 2062-2065.
4. Haisma HJ, et al. A monoclonal antibody-β-glucuronidase conjugate as activator of the prodrug epirubicin glucuronide for specific treatment of cancer. Br J Cancer 1992; 66: 474-478.
5. Houba PHJ, et al. Characterization of novel anthracycline prodrugs activated by human β-glucuronidase for use in antibody-directed enzyme prodrug therapy. Biochem Pharmacol 1996; 52: 45-63.
6. Bosslet K, Czech J, Hoffmann D. Tumor-selective prodrug activation by fusion protein-mediated catalysis. Cancer Res. 1994; 54: 2151-2159.
7. Vingerhoeds MH, et al. A new application for liposomes in cancer therapy. Immunoliposomes bearing enzymes (immuno-enzymosomes) for site-specific activation of prodrugs. FEBS Lett 1993; 336: 485-490.
8. Storm G, Vingerhoeds MH, Crommelin DJA, Haisma HJ. Immunoliposomes bearing enzymes (immuno-enzymosomes) for site-specific activation of anticancer prodrugs. Adv Drug Delivery Rev 1997; 24: 225-231.
9. Fonseca MJ, et al. Design of immuno-enzymosomes with maximum enzyme targeting capability. Effect of the enzyme density on the enzyme targeting capability and cell binding properties. Biochim Biophys Acta 1999; 1419: 272-282.
10. Haisma HJ, et al. Construction and characterization of a fusion protein of single-chain anti-carcinoma antibody 323/A3 and human β-glucuronidase. Cancer Immunol Immunother 1998; 45: 266-272.
11. Hanania EG, et al. Recent advantages in the application of gene therapy to human disease. Am J Med 1995; 99: 537-552.
12. Felgner PL, et al. Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc Natl Acad Sci USA 1987; 84: 7413-7417.
13. Caplen NJ, et al. Liposome-mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis. Nat Med 1995; 1: 39-46.
14. Lutz J, et al. Acute toxicity and depression of phagocytosis in vivo by liposomes: influence of lysophosphatidylcholine. Life Sci 1995; 56: 99-106.
15. Cherng JY, et al. Effect of size and serum proteins on transfection efficiency of poly((2-dimethylamino)ethyl methacrylate)-plasmid nanoparticles. Pharm Res 1996; 13: 1038-1042.
16. Huber BE, Richards CA, Austin EA. VDEPT; An enzyme/prodrug gene therapy approach for the treatment of metastatic colorectal cancer. Adv Drug Delivery Rev 1995; 17: 279-292.
17. Topf N, Worgall S, Hackett NR, Crystal RG. Regional 'pro-drug' gene therapy: intravenous administration of an adenoviral vector expressing the E. coli cytosine deaminase gene and systemic administration of 5-fluorocytosine suppresses growth of hepatic metastasis of colon carcinoma. Gene Ther 1998; 5: 507-513.
18. Jarnagin WR. Cationic lipid-mediated transfection of liver cells in primary culture. Nucleic Acids Res 1992; 20: 4205-4211.
19. Stephan DJ, et al. A new cationic liposome DNA complex enhances the efficiency of arterial gene transfer in vivo. Hum Gene Ther 1996; 7: 1803-1812.
20. Curiel DT, et al. High efficiency gene transfer mediated by adenovirus coupled to DNA-polylysine complexes. Hum Gene Ther 1992; 3: 147-154.
21. Ferrari S, et al. ExGen 500 is an efficient vector for gene delivery to lung epithelial cells in vitro and in vivo. Gene Ther 1997; 4: 1100-1106.
22. Goldman CK, et al. In vitro and in vivo gene delivery mediated by a synthetic polycationic amino polymer. Nat Biotech 1997; 15: 462-466.
23. Dodds E, et al. Lipofection of cultured mouse muscle cells: a direct comparison of Lipofectamine and DOSPER. Gene Ther 1998; 5: 542-551.
24. Van de Wetering P, et al. Relation between transfection efficiency and cytotoxicity of poly(2-dimethylamino)ethyl methacrylate)/plasmid complexes. J Control Rel 1997; 49: 59-69.
25. Marais R, et al. A cell surface tethered enzyme improves efficiency in gene-directed enzyme prodrug therapy. Nat Biotech 1997; 15: 1373-1377.